Prospective Repeated-Measures Study of Popliteal Vein Diameter During the First 48 Hours After Commercial Air Travel to Bogota for a Plastic Surgery Intervention

September 2, 2026 updated by: Research Inc
This prospective repeated-measures study will evaluate how long popliteal vein dilation persists after international commercial air travel to Bogota. Adult medical travelers will undergo standardized bilateral popliteal vein ultrasound within 24 hours before departure, within 2 hours after arrival, and at 24 and 48 hours after arrival, all before surgery. The primary outcome is change in mean bilateral popliteal vein diameter over time.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Eligible international travelers will complete a standardized preflight ultrasound and three postarrival examinations before surgery or intravenous fluid therapy. Each scan will be performed after a fixed resting period using the same popliteal landmark, minimal transducer pressure, and triplicate bilateral measurements. Flight duration, class, seat characteristics, movement, fluid intake, compression stocking use, and venous risk factors will be recorded. Mixed-effects analysis will estimate the postflight diameter and cross-sectional-area trajectory and the proportion returning to within 10% of baseline by 48 hours.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult international medical travelers completing a commercial flight of at least 4 hours to Bogota and undergoing all ultrasound measurements before surgery.

Description

Inclusion Criteria:

  • Age 18 to 65 years.
  • International commercial flight to Bogota with total airborne time of at least 4 hours.
  • Preflight baseline ultrasound obtained within 24 hours before departure using the standardized protocol.
  • Arrival ultrasound completed within 2 hours after reaching the study site and before surgery or intravenous fluid therapy.
  • Availability for 24-hour and 48-hour examinations.
  • Written informed consent.

Exclusion Criteria:

  • Known current deep venous thrombosis or pulmonary embolism.
  • Therapeutic anticoagulation at enrollment.
  • Major lower-extremity venous surgery, active leg infection, or condition preventing popliteal ultrasound.
  • Surgery, prolonged immobilization, or substantial intravenous fluid administration before completion of the 48-hour measurement.
  • Pregnancy.
  • Nondiagnostic baseline examination or inability to reproduce the landmark.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Postflight Repeated-Measures Cohort
All participants undergo standardized preflight and postarrival bilateral popliteal vein ultrasound without assignment to a travel intervention.
Other: Commercial Air Travel Exposure
Participants complete a commercial flight of at least 4 hours to Bogota. Flight duration, connections, cabin class, seat characteristics, movement, fluid intake, alcohol, sedatives, and compression stocking use will be recorded. Linked arm/group(s): Postflight Repeated-Measures Cohort.
Diagnostic test: Standardized Bilateral Popliteal Vein Duplex Ultrasound
After at least 10 minutes of supine rest, the popliteal vein will be imaged at a fixed landmark with minimal probe pressure. Anteroposterior and transverse diameters, cross-sectional area, compressibility, and flow will be recorded in both legs, with three repeated measurements averaged. Linked arm/group(s): Postflight Repeated-Measures Cohort.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Mean Bilateral Popliteal Vein Diameter
Time Frame: Within 24 hours before departure; within 2 hours after arrival at the study site; 24 +/- 2 hours after arrival; and 48 +/- 2 hours after arrival. 1 week
At each visit, the mean of three anteroposterior diameter measurements in each leg will be calculated, followed by the mean of both legs. Change from the participant's preflight value will be reported in millimeters and as percent change.
Within 24 hours before departure; within 2 hours after arrival at the study site; 24 +/- 2 hours after arrival; and 48 +/- 2 hours after arrival. 1 week

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Return of Popliteal Vein Diameter to Baseline
Time Frame: 24 +/- 2 hours and 48 +/- 2 hours after arrival. 1 week
Proportion of participants whose mean bilateral diameter is within plus or minus 10% of their preflight value.
24 +/- 2 hours and 48 +/- 2 hours after arrival. 1 week
Incidental Venous Thrombosis or Abnormal Compressibility
Time Frame: From preflight baseline through 48 hours after arrival. 1week
Number and proportion of participants with a new noncompressible venous segment or other finding requiring diagnostic clinical evaluation. This research protocol is not designed as a definitive thrombosis screening examination unless the final duplex protocol is expanded.
From preflight baseline through 48 hours after arrival. 1week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Research Inc

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Hugo Aguilar, MD, plastic surgery

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 12, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 2, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 2, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 8, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 8, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 2, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 015 (Other Identifier: Nahrain Medical Research Collective (NMRC))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

not contempled in the patient informed consent

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings